Cagrilintide

Weight Loss Phase 3

Long-acting amylin receptor agonist

Mechanism of Action

Activates amylin receptors, promoting satiety, slowing gastric emptying, and potentially preserving beta-cell function.

1,824
Community Posts
316
Users Discussing
11
Research Articles

Reported Outcomes

Clinical Strength: C (8 trials)

Based on community reports (1,824 posts). Grade reflects frequency and consistency of positive mentions.

B Appetite Suppression
247 mentions

Reduced hunger and food cravings

C Weight Loss
141 mentions

Reduction in body weight

C Sleep Quality
143 mentions

Effects on sleep quality

C Energy Levels
145 mentions

Changes in energy and fatigue levels

D Mental/Mood
44 mentions

Effects on mood and cognitive function

D GI Health
62 mentions

Gastrointestinal effects

D Blood Sugar Control
45 mentions

Improved glycemic control and insulin sensitivity

D Body Composition
21 mentions

Changes in muscle vs fat ratio

D Cardiovascular
26 mentions

Effects on heart health markers

Side Effects

Based on 168 user reports. Frequency indicates how often each was mentioned.

Common (>5%)

Fatigue
Mild 41 reports 20.7%
Constipation
Mild 32 reports 16.2%
Nausea
Mild 26 reports 13.1%
Insomnia
Mild 10 reports 5.1%

Uncommon (1-5%)

Stinging
Mild 9 reports 4.5%
Food Noise
Mild 9 reports 4.5%
Tiredness
Mild 9 reports 4.5%
Burning
Mild 8 reports 4.0%
Injection Site Reaction (Isr)
Mild 8 reports 4.0%
Hair Loss
Mild 7 reports 3.5%
Exhaustion
Mild 7 reports 3.5%
Increased Hunger
Mild 7 reports 3.5%
Sleepiness
Mild 6 reports 3.0%
Anhedonia
Mild 6 reports 3.0%
Water Retention
Mild 5 reports 2.5%
Injection Site Reaction
Mild 5 reports 2.5%
Acid Reflux
Mild 5 reports 2.5%
Sulfur Burps
Mild 5 reports 2.5%
Headaches
Mild 5 reports 2.5%
Diarrhea
Mild 5 reports 2.5%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

!

Pancreatitis

12 mentions

Rare but serious. Stop medication and seek care for severe persistent abdominal pain.

!

Thyroid Concerns

7 mentions

GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in rodents. Contraindicated in MEN2 or personal/family history of MTC.

!

Gallbladder Issues

3 mentions

Rapid weight loss increases gallstone risk. Report severe abdominal pain to healthcare provider.

!

Hypoglycemia Risk

14 mentions

Risk increases when combined with insulin or sulfonylureas. Monitor blood sugar carefully.

!

Psychiatric Effects

12 mentions

Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.

i

Gastrointestinal Issues

71 mentions

GI side effects are the most commonly reported. Usually improve over time with slow titration.

i

Injection Site Reactions

21 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose
0.3mg weekly (research protocols)
Titration
Titrate over weeks to target dose
Half-life
~7 days
Administration
Subcutaneous injection, once weekly

Community Dosing Patterns

Based on 221 mentions

Community-reported patterns, not medical advice.

0.25mg weekly
12
0.5mg weekly
6
1mg weekly
6
0.3mg weekly
5
500mcg weekly
4

Pricing

Research-grade reference pricing for 5mg vial. Prices vary by vendor and quantity.

We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.

US Research Grade

$80

Single small vial from US domestic vendors

US Research Grade (Bulk)

$32

Per-dose equivalent when buying larger US vials

China Research Grade

$8.5

Per-vial when buying 10-pack from Chinese vendors

89% savings

Research

11
Total Articles
8
Clinical Trials
7
Reviews

Key Studies

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis meta_analysis

BMJ (2024)

Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity Review

Int J Mol Sci (2024)

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis meta_analysis

Indian J Endocrinol Metab (2024)

A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance Preclinical

bioRxiv (2025)

Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Preclinical

Nat Commun (2025)

Commonly Stacked With

Based on 1,824 community posts mentioning Cagrilintide.

Retatrutide 498 mentions (27.3%)
Tirzepatide 99 mentions (5.4%)
Semaglutide 55 mentions (3%)
MOTS-c 32 mentions (1.8%)
Tesamorelin 17 mentions (0.9%)

Switching Patterns

Based on 154 discussions about switching to or from Cagrilintide.

→ Switching FROM

Retatrutide 36 mentions
Tirzepatide 10 mentions

Users who switched to Cagrilintide

← Switching TO

Retatrutide 27 mentions

Users who switched from Cagrilintide

Frequently Asked Questions

What is cagrilintide?

Does cagrilintide help with weight loss?

Does cagrilintide reduce appetite?

Can cagrilintide be combined with semaglutide?

Can cagrilintide be combined with tirzepatide?